| Charaia A Hill, ACNP-BC | |
|
539 Egg Harbor Rd Ste 1, Sewell, NJ 08080-2371 | |
| (856) 589-0300 | |
| (856) 589-1753 |
| Full Name | Charaia A Hill |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 539 Egg Harbor Rd Ste 1, Sewell, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134472186 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 26NJ00398300 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jefferson Stratford Hospital | Stratford, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
The federal government Thursday lowered a year's worth of Medicare payments to 751 hospitals to penalize them for having the highest rates of patient injuries.
A Senate vote on the package is set for today. The deal itself has left both liberals and conservatives unhappy but clarified both parties' priorities. For Democrats, it was protecting Medicaid and Social Security. For Republicans, preventing tax increases.
A new meta-analysis has found that delirium, a condition developed by many patients in hospital intensive care units (ICU), is associated with higher mortality rates, more complications, longer stays in the ICU, and longer hospitalizations.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.
› Verified 9 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
The federal government Thursday lowered a year's worth of Medicare payments to 751 hospitals to penalize them for having the highest rates of patient injuries.
A Senate vote on the package is set for today. The deal itself has left both liberals and conservatives unhappy but clarified both parties' priorities. For Democrats, it was protecting Medicaid and Social Security. For Republicans, preventing tax increases.
A new meta-analysis has found that delirium, a condition developed by many patients in hospital intensive care units (ICU), is associated with higher mortality rates, more complications, longer stays in the ICU, and longer hospitalizations.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.
› Verified 9 days ago
| Entity Name | Lourdes Cardiology Services, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912202557 PECOS PAC ID: 5799961751 Enrollment ID: O20110510000163 |
News Archive
The federal government Thursday lowered a year's worth of Medicare payments to 751 hospitals to penalize them for having the highest rates of patient injuries.
A Senate vote on the package is set for today. The deal itself has left both liberals and conservatives unhappy but clarified both parties' priorities. For Democrats, it was protecting Medicaid and Social Security. For Republicans, preventing tax increases.
A new meta-analysis has found that delirium, a condition developed by many patients in hospital intensive care units (ICU), is associated with higher mortality rates, more complications, longer stays in the ICU, and longer hospitalizations.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charaia A Hill, ACNP-BC 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0340 | Charaia A Hill, ACNP-BC 539 Egg Harbor Rd Ste 1, Sewell, NJ 08080-2371 Ph: (856) 589-0300 |
News Archive
The federal government Thursday lowered a year's worth of Medicare payments to 751 hospitals to penalize them for having the highest rates of patient injuries.
A Senate vote on the package is set for today. The deal itself has left both liberals and conservatives unhappy but clarified both parties' priorities. For Democrats, it was protecting Medicaid and Social Security. For Republicans, preventing tax increases.
A new meta-analysis has found that delirium, a condition developed by many patients in hospital intensive care units (ICU), is associated with higher mortality rates, more complications, longer stays in the ICU, and longer hospitalizations.
BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th. This represents the first IL-6 receptor inhibitor agent approved for Rheumatoid Arthritis (RA); Actemra is approved for adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Actemra represents the fourth IV Infusion product in the RA Market and the first infusion product with monthly maintenance dosing.
Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.
› Verified 9 days ago
Gloria L Jackson, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 900 Medical Center Dr Ste 200, Sewell, NJ 08080 Phone: 856-557-7900 | |
Rosalin Ivanay Thompson-cordoba, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 239 Hurffville Crosskeys Rd Ste 2, Sewell, NJ 08080 Phone: 856-262-8300 | |
Ms. Alaina Marie Guiliana, FNP-BC RN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 307 Egg Harbor Rd, Sewell, NJ 08080 Phone: 186-638-9272 | |
Mr. Michael Joseph Kinney, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 405 Hurffville Crosskeys Rd Ste 203, Sewell, NJ 08080 Phone: 856-582-0033 Fax: 856-582-2305 | |
Parminder Bath Sohal, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 900 Medical Center Dr Ste 200, Sewell, NJ 08080 Phone: 856-557-7900 | |
Dawn Topper, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Kings Way E Ste B1, Sewell, NJ 08080 Phone: 856-536-1515 Fax: 856-412-5324 | |
Mrs. Lisa Elizabeth Pope, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 555 Egg Harbor Rd, Sewell, NJ 08080 Phone: 856-582-2500 |